AIDS patients with bacterial lower respiratory tract infections: treatment with ofloxacin versus sulbactam-ampicillin

J Chemother. 1992 Dec;4(6):376-80. doi: 10.1080/1120009x.1992.11755466.

Abstract

In this open-label, randomized, parallel-groups study the Authors compare the parenteral administration of a beta-lactamase inhibitor associated with a semisynthetic penicillin (sulbactam-ampicillin) with the oral administration of a 3rd-generation quinolone (ofloxacin), in 20 HIV-infected subjects suffering from lower respiratory tract (LRT) infections. 12 patients were classified as AIDS, 6 as ARC (AIDS related complex) and 2 as asymptomatic seropositives. The risk of becoming HIV-infected and the work load for the health staff were also evaluated. The clinical and microbiological results indicate that oral ofloxacin is as effective as parenteral sulbactam-ampicillin for the treatment of LRT infections in HIV-positive individuals. In addition, the members of the health staff reported significantly less difficulty in administering ofloxacin in respect to sulbactam-ampicillin.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / microbiology
  • Adult
  • Ampicillin / therapeutic use
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / microbiology
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • Humans
  • Male
  • Ofloxacin / therapeutic use*
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology
  • Sulbactam / therapeutic use

Substances

  • Ampicillin
  • Ofloxacin
  • Sulbactam